Biogen Idec PT Raised to $300.00 (BIIB)
Research analysts at Jefferies Group boosted their price target on shares of Biogen Idec (NASDAQ:BIIB) to $300.00 in a report released on Tuesday, AmericanBankingNews.com reports. Jefferies Group’s target price would suggest a potential upside of 17.91% from the stock’s previous close.
In other Biogen Idec news, SVP Alfred Sandrock unloaded 15,030 shares of Biogen Idec stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $250.11, for a total transaction of $3,759,153.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
A number of other firms have also recently commented on BIIB. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Biogen Idec in a research note to investors on Monday. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Biogen Idec in a research note to investors on Sunday. Finally, analysts at Wells Fargo & Co. reiterated a “positive” rating on shares of Biogen Idec in a research note to investors on Tuesday, October 22nd. Eight research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Biogen Idec currently has a consensus rating of “Buy” and a consensus price target of $253.95.
Shares of Biogen Idec (NASDAQ:BIIB) traded down 0.35% during mid-day trading on Tuesday, hitting $253.5268. The stock had a trading volume of 451,443 shares. Biogen Idec has a 52 week low of $134.00 and a 52 week high of $242.64. The stock’s 50-day moving average is $218.0 and its 200-day moving average is $209.5. The company has a market cap of $60.256 billion and a P/E ratio of 37.69.
Biogen Idec (NASDAQ:BIIB) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $2.10 by $0.25. The company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.78 billion. During the same quarter in the prior year, the company posted $1.91 earnings per share. The company’s quarterly revenue was up 31.9% on a year-over-year basis. Analysts expect that Biogen Idec will post $8.62 EPS for the current fiscal year.
Biogen Idec Inc (NASDAQ:BIIB) is a global biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.